Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03235752
Recruitment Status : Completed
First Posted : August 1, 2017
Last Update Posted : January 5, 2021
Information provided by (Responsible Party):
I-Mab Biopharma HongKong Limited

Brief Summary:
This is a multicenter, randomized, double-blind, placebo-controlled phase II study.

Condition or disease Intervention/treatment Phase
Active Ulcerative Colitis Drug: TJ301 300mg Drug: TJ301 600mg Drug: Placebo Phase 2

Detailed Description:

is a multicenter, randomized, double-blind, placebo-controlled phase II study. The trial includes a Run-in Period (if stable conventional treatment needed), a 4-week Screening Period, a 12-week Treatment Period, and a 3-week Safety Follow-up Period to Day 105.

90 patients will be centrally, dynamically, randomly assigned to 3 groups (1:1:1) to receive 600mg TJ301 Q2W, 300mg TJ301 Q2W or placebo Q2W.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 91 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, Double-blind, Placebo-controlled
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Randomized, Double-blind, Placebo-controlled
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis
Actual Study Start Date : February 6, 2018
Actual Primary Completion Date : December 21, 2020
Actual Study Completion Date : December 21, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TJ301 300mg
TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
Drug: TJ301 300mg
TJ301 300mg IV infusion

Experimental: TJ301 600mg
TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
Drug: TJ301 600mg
TJ301 600mg IV infusion

Placebo Comparator: Placebo
Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
Drug: Placebo
Placebo IV infusion

Primary Outcome Measures :
  1. Clinical and endoscopy response [ Time Frame: Week 12 ]
    Clinical and endoscopy response (decrease from Baseline in full Mayo score ≥3 and ≥30%, including decrease from Baseline in rectal bleeding subscore ≥1 or rectal bleeding subscore ≤1) at Week 12.

Secondary Outcome Measures :
  1. Clinical and endoscopy remission at Week 12 [ Time Frame: Week 12. ]
    Clinical and endoscopy remission at Week 12, defined as a full Mayo score ≤2, no individual subscore >1, rectal bleeding subscore = 0.

  2. Clinical remission at Weeks 4, 6, 8, 10, and 12 [ Time Frame: Weeks 4, 6, 8, 10, and 12 ]
    Clinical remission at Weeks 4, 6, 8, 10, and 12 defined as a stool frequency subscore=0, rectal bleeding subscore = 0, and 9-point partial Mayo score ≤1.

Other Outcome Measures:
  1. Change from Baseline to Weeks 4, 8, and 12 in exploratory biomarkers [ Time Frame: Baseline to Weeks 4, 8, and 12 ]
    Change from Baseline to Weeks 4, 8, and 12 in exploratory biomarkers (erythrocyte sedimentation rate [ESR], C-reactive protein (CRP), IL-6, IL-6/sIL-6R complex, neutrophil and platelet count, faecal calprotectin).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female patients 18-70 (inclusive) years of age.
  2. Hisory of active UC of more than 3 months. Active UC confirmed by colonoscopy with biopsy or flexible sigmoidoscopy with biopsy at Screening, with extending > 15-cm past the anal verge from endoscopy. Biopsy sample is not necessary if UC is already confirmed.
  3. Active UC with a full Mayo score≥5 and a rectal bleeding subscore ≥1 at screening.
  4. During Day -28 to Day -6 prior to Randomisation, an endoscopy subscore ≥2.
  5. Treated with conventional non-biological UC therapy: with corticosteroids stable for at least 2 weeks prior to Randomization at no more than 20 mg prednisone per day (or equivalent), and/or with medications containing 5-aminosalicylates (5-ASA) at no less than 2 g 5-ASA per day for at least 3 months and stable for at least 4 weeks prior to Randomization, and/or with azathioprine (AZA) at no less than 0.75 mg/kg/day or mercaptopurine (6-MP) at no less than 0.5 mg/kg/day for at least 6 months and stable for at least 6 weeks prior to Randomization, or MTX no less than 12.5 mg/week and stable for at least 12 weeks prior to Randomization.
  6. Male subjects and female subjects of child bearing potential must have been willing to practice effective contraception during the study and been willing and able to continue contraception for 1 month after their last dose of the study treatment.
  7. The patient is able and willing to comply with the requirements of this trial protocol.
  8. The subject should be able to read and write to understand and fill out Patient Diary.
  9. Voluntarily signed Informed Consent obtained before any trial-related procedures are performed.
  10. The subject have not received any biologic therapies OR have received 1 biologic drug for the treatment of UC or immune diseases and the last dose must be longer than 8-week or a 5 half-life (whichever is longer) period prior to the first dose of study drug.

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Contraindication to colonoscopy or sigmoidoscopy.
  3. Allergies to any component of TJ301.
  4. Subject who is likely to receive surgery for UC treatment within 1 month based on investigator's evaluation.
  5. History of colostomy, colectomy or partial colectomy.
  6. Current diagnosis of inflammatory bowel disease unclassified, Crohn's disease, ischemic colitis, fulminant colitis and/or toxic megacolon, patients with ulcerative colitis limited to the rectum (ulcerative proctitis), infective enteritis, amebic bowel disease or intestinal schistosomiasis.
  7. History of malignancy other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. If the Screening colonoscopy shows evidence of dysplasia or a malignancy, the patient is not eligible.
  8. Primary or secondary immunodeficiency including neutropenia (absolute neutrophil count <1500/μL); or lymphopenia (absolute lymphocyte count <500/μL).
  9. Moderate to severe anaemia (haemoglobin <9 g/dL), or thrombocytopenia (platelet count <75 000/μL), or serum creatinine >2 mg/dL.
  10. Autoimmune disease besides UC, with the exceptions of Sjogren's syndrome or hypothyroidism.
  11. Clostridium (C.) difficile positive at screening visit or treated for C. difficile within the 4 weeks prior to Randomization.
  12. serum transaminases >2.5 x upper limit of normal [ULN], alkaline phosphatase >2.5 x ULN.
  13. Serious underlying disease other than UC in the opinion of the investigator.
  14. History of drug addiction within the last 1 year or current drug addiction or use of illicit drugs.
  15. Any indication of the regular use of more than 40 grams of alcohol every day.
  16. Smokers who smoke more than 10 cigarettes per day.
  17. Known concurrent acute or chronic viral hepatitis B or C infection or human immunodeficiency virus (HIV) infection.
  18. Presence or history of active tuberculosis (TB) or latent TB infection, defined as 1) a positive QuantiFERON-TB Gold test at Screening; or 2) a T-spot test within 4 weeks of Randomisation and evidence of current or previous pulmonary tuberculosis by low-dose CT or chest X-ray within 12 weeks of Randomisation. Patients with old TB will also be excluded.
  19. Positive immunoglobulin M antibody titres to Epstein-Barr virus (EBV).
  20. Subjects with positive results for cytomegalovirus at screening are to be excluded.
  21. Receiving any investigational therapy or any approved therapy for investigational use within 30 days or 5 half-lives prior to Randomization (whichever is longer).
  22. Currently taking any medications other than those allowed per protocol guidelines.
  23. Infections (including diverticulitis) requiring treatment with antibiotics, antivirals, or antifungals within 14 days prior to Randomisation.
  24. Received any live (attenuated) vaccines within 30 days prior to Randomisation.
  25. Recent treatment with medium-to-high-dose intravenous corticosteroids (methylprednisolone 60 mg/day or hydrocortisone 300 mg/day) within 8 weeks prior to Randomisation or oral corticosteroids of more than 20 mg prednisone per day (or equivalent).
  26. Receipt of cyclosporine, tacrolimus, sirolimus, thalidomide, or mycophenolate mofetil within 30 days prior to Randomisation.
  27. Treatment with therapeutic enema or suppository, other than required for endoscopy preparation, within 14 days prior to the screening endoscopy and during the remainder of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03235752

Show Show 27 study locations
Sponsors and Collaborators
I-Mab Biopharma HongKong Limited
Layout table for investigator information
Principal Investigator: Minhu Chen, Doctor First Affiliated Hospital, Sun Yat-Sen University
Layout table for additonal information
Responsible Party: I-Mab Biopharma HongKong Limited Identifier: NCT03235752    
Other Study ID Numbers: CTJ301UC201
First Posted: August 1, 2017    Key Record Dates
Last Update Posted: January 5, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by I-Mab Biopharma HongKong Limited:
Active Ulcerative Colitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases